Member Info for raharh

eva20 - i think you answered both questions at once !

Thank you

Excellent find. Although I do have a few questions.

1. Is this the same ELISA test ?

2. How will this interfere with Omega, is it a conflict?

To guarantee access to the technology among low income settings, Mologic has established an independent manufacturing facility that is delinked from commercial return. Global Access Diagnostics is nearing completion and will manufacture up to 40 million devices per annum with a target price of £1.

If in production would Omega post an RNS when production under way?

Tiptree - i have been convincing myself there must be a downside for a week or two and gave in today and bought more. Ultimately this isnt just a Covid stock. Immutex itself will return more than current SP if listed / sold at a similar value.

More than that you buy into business and leadsership and I think CF is the real deal, he has £2m invested and will not want this to go cheap - clear mentality on his approach - acquire businesses, right size and remove costs that are not needed, make them operationally profitable and open up there potential then sell them.

If they do go through a sale my first bit of research will be; Where has CF gone now?

Complex area - CF promoting OPEN and i think the B2B is probably the right way to go. It looks like POC Finger Prick tests will come through the RTC looking at the press release today and is government sponsored so there will be the three anti body routes:
NHS - Roche and Abbot
Private / Corporate - Open
Self / Voluntary - POC-RTC (ODX only AIM company involved in this)

Corporate will want 100% due liabilities and duty of care so I think there is room for all three for a good period of time.

NST - Agreed, pretty much stuck to script but the one bit that he gave a little more light on was timescales for Immutex. Previously months not years, now i think he said 4 months (3 - 4 or 4 - 5 - my internet cut out).

That's me done, hold for that period at least and let the other news flow, if they are signing up 3 challenge studies this month they will definitely be RNS as new line of business.

Nothing not to like.

www.sharesmagazine.co.uk/events

Cathal is doing the rounds at the moment and i think it will be similiar to last weeks update where he was definately putting Immutex in the shop window and ensuring everyone knows the multiple revenue streams that are in operation. Anything that would be big news would have to be RNSd unless he says it tonight and RNS in the morning at 7am? Will however be watching with interest.

It is 46k per day for Mologic

So earlier i did not read the press release part. I stopped after the RNS part and thought; 'Thats not much of an update'. Now i have re-read the RNS including the press release it is very positive. Tied to NHSX and with Omega in the manufacturing this is not only comforting but quite exciting. Nearly there!

I think it will depend on news flow. If they can get the Quotient machine running at capacity and the challenge studies up and running it could get to 20p quicker. Personally I am waiting for the immutex situation to reach a resolution before thinking where to have a target.

Sparkington I agree.

He was asked about the £100m and he smiled and said that we were in a different place. 15p shows an £80 MCAP.

Challenge Study Revenues for Covid-19 (c.£90m)
Letting out lab space
Quotient Revenues
Immutex sale / Nasdaq list (which he assured would be paid as dividend if sold and in months not years)
Venn database subscription

A lot of revenue streams.

I think he said always up for sale but not at £100m - multiples of (I took £300m-£500m - not £200m) and so I think the SP has many levels to go if you hold over time.

He may be the largest shareholder and so has vested interest and is tied in for three years, he is uncovering what he has and knows how to take advantage commercially of unfortunate market conditions with the pandemic to help but also increase the business. It is now worth a lot more and he knows it as a serial entrepeneur. Hands on and clued up so I think 15p is nothing compared to where this could go.

PROP5 - i am in the same boat, wonder if we are talking about the same one

Give me an A ....
Give me a ....

Maybe not - but my head is in the same place, I just need to release funds and an RNS elsewhere will do that.

At best this will consolidate in the 70 - 80 range wont it. Just gives confidence that the freeze is on they way.

Is this actually news? Just says we expect a design Freeze in June (didnt we already?). I am not ramping or de-ramping - I am a holder - but not sure what this adds other a timescale we all thought was happening. The big danger is not reaching a freeze in June now.

I have to take my hats off to you long term AIM investors. I have been on AIM for three months, not even an investor really but in lock down it provided a distraction. I have an extremely small pot (less than £5k across three of my holdings). I have panic sold, panic re-bought and everything inbetween over three months and although I am up about 10% had I had mental fortitude I could have been up by 30 - 40%. Not life changing, something that I wanted as a distraction as working at home and sat in front of my laptop all day is pretty boring.

The one point i do agree with on AIM is mental fortitude, I firmly believe in all three of my shares now but in the three months I have sold and re-bought them all in blind panic. I am now sitting for the longest period in three months without a trade and it is tough.

I really need to get out to work so i am not on google refreshing boards and SPs, either that or I need to hit my personal target (I am not looking to pay off the mortgage!) and then get out.

AIM is not for the faint hearted by any stretch.

But on Avacta - I think it has massive potential and I am awaiting the Adeptrix news first, this will confirm the Cytvia news I think. A pharma partnership on the treatment would be a cherry on the top.

So on the proactive investors day I wanted to clarify if Open were going to supply to government due to the scottish parliament question. Which they clarified they were not - they were targetting private practice.

However I did get a reply from Cathal the following day:

Under stock exchange rules i.e. market sensitive inside information, we are unable to share information as regards order flows, however, as always, when we have updates will let the market now. Furthermore, we’ve made it clear that when we reach capacity we will get a second machine from Quotient. Likewise it’s our intention to serve all of the UK from our London clinic and possibly also the Republic of Ireland. Again we’ll update the market as regards any new or exciting developments on that regards.

So I dont think they have a second machine yet - they hopefully would RNS this as it would be coupled with revenues.

If the company sells everyone will get a per share price - as he has the largest holder it will benefit him most. They are intrinsically linked. My view of his 'talking the SP down' was almost a hidden message to PIs telegraphing the capital raise to manage the share price until the rise was done. At the time I was unimpressed, but as the weeks have unfolded since that, I am actually more impressed. He seems shrewd and switched on, if someone doesnt have faith in the CEO of an AIM company they are probably invested in the wrong one. I have faith.

A bit weird today - it is almost no update and so lets have some questions and be done. I would be surprised see any thing further from John Newton - that does not provide any come back for questions today. Does not affect my views on the investment but it feels like a non event today.

For once I sat on my hands .... I am learning .. slowly .... but i have ridden the drops here and on Avacta and plan to hold now.

In addition I am sure that Avacta indicated that the Adeptrix news would come first (did I dream that!?!) and so I am not sure we are waiting for Cytvia at the moment. They were also looking to partner on the treatment and signing a partnering agreement could be next so I think Cytvia will either be the second or third of the RNSs due.